Profound Medical Reclaims Distribution Rights for TULSA-PRO in Canada
In a significant move for the medical device industry, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has successfully regained exclusive distribution rights for its TULSA-PRO technology in Canada. This announcement marks a pivotal turn in the company’s efforts to expand access to its innovative, MRI-guided therapies for prostate conditions.
The TULSA Procedure and Its Benefits
The TULSA Procedure is a cutting-edge technique utilized by healthcare professionals to effectively ablate prostate tissue in patients dealing with prostate cancer and benign prostatic hyperplasia (BPH). This non-invasive approach utilizes advanced robotics and imaging technology to target and treat diseased tissue with precision, significantly reducing recovery times compared to traditional surgical methods.
“Currently, there is only one site in Canada deploying the TULSA Procedure, located at the esteemed Sunnybrook Health Sciences Centre,” remarked Arun Menawat, the CEO and Chairman of Profound Medical. This facility has taken the lead, performing over 100 successful procedures, showcasing the technology's efficacy and safety profile.
Transitioning from Knight Therapeutics
Previously, Knight Therapeutics acted as the exclusive distributor of the TULSA-PRO system in Canada since an agreement was made in April 2015. Profound has now transitioned back to direct control of distribution, paying CDN$90,000 (US$64,000) and committing to a 5% royalty on net sales for the next 15 years. This strategic move allows Profound to leverage its comprehensive knowledge and resources to enhance the TULSA-PRO reach within Canada.
Samira Sakhia, the President and CEO of Knight, praised Profound's commitment to innovation in the medical field, asserting that their partnership has served the healthcare community well. She emphasized that the unique complexities of the TULSA technology necessitate direct engagement from Profound’s teams in North America.
Plans for Expansion and Clinical Research
Looking forward, Profound aims to enhance access to the TULSA Procedure while aligning with provincial health authorities to facilitate public insurance coverage. As the company anticipates results from the CAPTAIN trial, which will compare the TULSA Procedure with traditional robotic prostate surgery, it hopes to advocate for broader acceptance of this novel treatment method across Canadian hospitals.
The Technology Behind TULSA-PRO
The TULSA-PRO system merges real-time MRI technology with AI capabilities, ensuring tailored treatment plans for each patient. Through robotic guidance and transurethral ultrasound, the procedure accurately targets prostate tissue while minimizing damage to surrounding areas. This innovation results in a less invasive approach, avoiding prolonged hospital stays and leading to faster recoveries for patients.
Profound Medical's commitment to safety and efficacy is highlighted by the fact that no bleeding occurs during the procedure, and most patients return to their regular schedules shortly thereafter, experiencing minimal disruption to their lives.
Market Potential and Future Innovations
With growing interest in its technologies, Profound is currently reinforcing its direct sales efforts throughout North America, while also establishing partnerships with key distributors globally. Such proactive measures will help the company tap into new markets and elevate its profile in the medical community.
The TULSA-PRO system not only addresses prostate issues but also opens avenues for treating other medical conditions with similar therapeutic principles. The technology holds promise in various treatment arenas, potentially benefitting numerous patients worldwide.
Profound also continues to develop additional technologies like Sonalleve®, targeting uterine fibroids and other ailments, thus positioning itself as a leader in non-invasive treatment technologies.
Frequently Asked Questions
What is TULSA-PRO?
TULSA-PRO is an AI-powered, MRI-guided system designed for the precise ablation of prostate tissue, providing a minimally invasive alternative to traditional prostate surgeries.
Why has Profound Medical regained distribution rights?
Profound regained the rights to better manage the distribution and expand access to the TULSA Procedure in Canada, following a cash payment and a royalty agreement with Knight Therapeutics.
Where is the TULSA Procedure currently offered in Canada?
As of now, the TULSA Procedure is offered at Sunnybrook Health Sciences Centre in Toronto, where over 100 successful procedures have been performed.
How does the TULSA technology compare to traditional methods?
The TULSA technology offers a less invasive treatment option, eliminating needs for dangerous surgeries and lengthy recoveries often associated with traditional prostate cancer treatments.
What are Profound Medical's future plans for TULSA-PRO?
Profound aims to secure broader insurance coverage and expand its network of treatment centers while continuing its research and development efforts in innovative medical therapies.
